Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
Rhea-AI Summary
Silo Pharma (Nasdaq: SILO) announced that its wholly owned AI subsidiary QwikAgents has engaged Caylent, an Amazon Web Services (AWS) Premier Tier Services Partner, to design and build a new AWS-native QwikAgents platform.
According to Silo Pharma, Caylent will create a fresh AWS-native foundation rather than migrate the existing application, preserving QwikAgents’ core functionality while enhancing scalability, performance and security for enterprise deployment and future product innovation. The engagement is structured to align with AWS funding programs, with funding support expected from AWS and Caylent. Silo highlights this collaboration as a key step in positioning QwikAgents for enterprise growth and in supporting the long-term commercialization strategy alongside its biopharmaceutical pipeline targeting PTSD, fibromyalgia, chronic pain and Alzheimer’s disease.
Positive
- AWS-native rebuild with Caylent expected to enhance scalability, performance and security for QwikAgents
- Engagement aligned with AWS funding programs with funding support expected from AWS and Caylent
- Platform positioned for enterprise deployment to support long-term commercialization of QwikAgents
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | AI platform progress | Positive | +0.2% | QwikAgents commercialization progress and SPC-15 development update |
| Jul 14 | AI developer program | Positive | -2.8% | QwikAgents joined AMD program with developer resources and cloud credits |
| Jul 10 | Private placement | Negative | -26.3% | Equity and warrant financing announced with approximately $4 million upfront proceeds |
| Jul 07 | AI developer program | Positive | -9.0% | QwikAgents joined NVIDIA program to support enterprise AI platform development |
| Jun 29 | Drug-device study | Positive | +0.3% | SPC-15 robustness study preceded planned FDA Type C meeting request |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions diverged across announcements, with AI-platform updates ranging from -9% to +0.21%.
Key Terms
aws-native technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption
SARASOTA, FLA., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a managed AI agent platform and developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that its wholly owned subsidiary, QwikAgents, has engaged Caylent, a cloud services company and Amazon Web Services (AWS) Premier Tier Services Partner, to design and build an AWS-native QwikAgents platform.
The collaboration represents the next phase in the evolution of the QwikAgents platform. Rather than migrating the existing application, Caylent will build a new AWS-native foundation that preserves QwikAgents' core functionality while enhancing scalability, performance and security for enterprise deployment and future product innovation. The engagement is also structured to align with AWS funding programs, with funding support expected from AWS and Caylent.
“This collaboration is an important step in positioning QwikAgents for enterprise growth,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “By combining our AI platform with Caylent's AWS expertise, we're creating a scalable foundation to accelerate commercialization and future innovation.”
The AWS-native platform is expected to enhance the scalability, performance and security of QwikAgents while accelerating future product development and supporting the platform's long-term commercialization strategy.
About Silo Pharma, Inc.
QwikAgents, Silo Pharma's wholly owned artificial intelligence subsidiary, is a managed AI agent platform that delivers dedicated autonomous agents for research, content generation, scheduling, and workflow automation — each running in a persistent environment with proprietary smart-routing across multiple AI models. The subsidiary reflects Silo's strategy to expand into high-growth technology markets while continuing to advance its core biopharmaceutical pipeline. qwikagents.com
Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
(800) 705-0120
investors@silopharma.com
